Call for Abstracts
Abstract submission deadline
3:00pm, September 30, 2021 (Japan Standard Time, UTC+9)
Extended to 12:00p.m., November 1, 2021 (Japan Standard Time, UTC+9)
Call for Abstracts is now closed.
Eligibility
In principle, the first author must be a member of the Japanese Society for Transplantation and Cellular Therapy (JSTCT) at the time of abstract submission. However, this excludes residents and undergraduate students (who must submit a separate certificate), and those who belong to institutions or organizations outside Japan.
To submit an abstract, the following criteria must be met:
The content of the submitted abstract must fit into one of the JSTCT2022 Abstract Review Categories.
Abstracts with the same content as a paper already submitted to a journal will be accepted for submission if it has not yet been published.
If you are registering additional content to previously published work, it must contain important new information, or the conclusions must be different due to the addition of new data.
Abstracts presented at other conferences will be accepted if the language of the abstract and presentation is different (e.g., English ⇆ Japanese).
Any of the following criteria will make an abstract ineligible for presentation:
The same content has already been published in an academic journal at the time of abstract submission.
The same content has already been presented in other academic meetings at the time of abstract submission.
Abstract submission guidelines
- 1. All applicants are required to create a user account first. After creating the account, you can submit your abstract for this annual meeting with the account.
- 2. Once the submission is completed, A confirmation email will be sent automatically. If you do not receive the confirmation e-mail within 24 hours after submission, please contact the Conference Secretariat (jstct2022@jtbcom.co.jp).
- 3. Abstract number will be generated automatically when an abstract is submitted.
- 4. For changes, withdrawal or additional submission, please log in to the system using your ID and password from "Abstract Submission" button at the bottom of this page.
Application for general presentation (paper/poster)
1. Select the desired style of your presentation
Submitted abstracts will be chosen for Oral presentation or Poster presentation depending on the results of peer review.
ORAL PRESENTATION:
PC presentation only (film slides or videotapes are not allowed)
POSTER PRESENTATION:
Discussion in the Poster
2. Select an appropriate category from the following list
| Main Category |
Sub Category |
| 01. Stem Cell Biology |
|
| 02. Histocompatibility Antigen |
|
| 03. Stem Cell Mobilization and Harvest |
|
| 04. Stem Cell Source |
|
| 05. Conditioning Regimens |
|
| 06. Supportive Care |
|
| 07. Transplant Immunity |
07-1. Immune Reconstitution |
| 07-2. Acute GVHD |
| 07-3. Chronic GVHD |
| 07-4. GVL |
| 07-5. Others |
| 08. Immunotherapy / Cell therapy / Gene therapy |
08-1. Preclinical |
| 08-2. Clinical |
| 09. Child-specific Transplant Disease (Inborn errors of metabolism, Congenital immune deficiency and others) |
|
| 10. Transplant Outcomes |
10-1. Acute Leukemia |
| 10-2. Myelodysplastic Syndrome / Myeloproliferative Tumor |
| 10-3. Malignant Lymphoma/ATL |
| 10-4. Multiple Myeloma/Plasma Cell Disorders |
| 10-5. Aplastic Anemia |
| 10-6. Others |
| 11. Minimal Residual Disease and Relapse |
|
| 12. Early Complications |
12-1. Engraftment Failure |
| 12-2. TMA |
| 12-3. VOD/SOS |
| 12-4. Others |
| 13. Late Complications |
|
| 14. Infection |
14-1. Bacterial Infection |
| 14-2. Fungal Infection |
| 14-3. Viral Infection |
| 14-4. Others |
| 15. Follow-up and QOL |
|
| 16. Marrow Donor Program / Cord Blood Bank / Donors |
|
| 17. Hematopoietic Cell Transplant Coordinator and Coordinate |
|
| 18. Care |
18-1. Oral Care |
| 18-2. Skin Care |
| 18-3. GVHD Care |
| 18-4. Mental Care |
| 18-5. Others |
| 19. Management |
19-1. Infection Control |
| 19-2. Meal Management |
| 19-3. Nutrition Management |
| 19-4. Others |
| 20. Rehabilitation |
|
| 21. Nursing / Education |
|
| 22. TDM / Drugs |
|
| 23. Team Medical-care |
|
Guidelines for abstract preparation
- 1. The title should be no longer than 100 characters including spaces. Affiliation(s) should be written concisely and the abstract no longer than 1800 characters including spaces. In case you need to add an image (picture, chart or diagram) in your abstract, the word limitation will be reduced to 900 characters.
- 2. The abstract should be arranged under the following headings: Objective, Subjects and Methods, Results, Conclusions. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and if relevant, Conclusions).
- 3. Presentations, abstracts and presentation data must be prepared in English.
- 4. See below for declaration of conflict of interests.
- 5. On abstract submission form, please select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
In the case that a presentation theme relates to “Ethical guidelines for Clinical Research”, the approval of the Institutional Review Board (IRB) or the Ethical Review Board (ERB) is required. Please refer to
the guideline of the Ministry of Education, Culture, Sports, Science and Technology website.
Conflict of interest
- 1. When you submit an abstract, please report whether there are potential conflicts of interest with companies concerned with the content of your presentation within the last three years.
- 2. The authors (include co-authors) are required to disclose applicable COI by displaying a COI disclosure slide at the beginning of presentation slides (the slide after the title of presentation and the name of presenters) or at the end of a poster using samples as attached.
Personal information protection
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/abstract book and on the website, but not for other purposes. The registration process for applications has been commissioned to the Conference Secretariat c/o JTB Communication Design, Inc. in order to facilitate management operations
Submission policy
You can check and modify your abstract as many times as you like until the deadline for abstract submission. Abstracts generally may not be revised or withdrawn after the deadline for abstract submission. However, abstracts may be withdrawn within 14 days of notification of acceptance or rejection, presentation type and the presentation language.
Notification of Abstract Acceptance/Rejection and Presentation Date
Notification of acceptance or rejection of abstracts and the date and time of presentation will be sent by e-mail around the end of November. The results will also be posted on this website.
